TY - JOUR A1 - Ullmann, Andrew J. A1 - Schmidt-Hieber, Martin A1 - Bertz, Hartmut A1 - Heinz, Werner J. A1 - Kiehl, Michael A1 - Krüger, William A1 - Mousset, Sabine A1 - Neuburger, Stefan A1 - Neumann, Silke A1 - Penack, Olaf A1 - Silling, Gerda A1 - Vehreschild, Jörg Janne A1 - Einsele, Hermann A1 - Maschmeyer, Georg T1 - Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016 JF - Annals of Hematology N2 - Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations. This is the updated version of the AGHIO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria. KW - Bone-marrow-transplantation KW - Pneumocystis-carinii-pneumonia KW - Influenzae type B KW - Respiratory syncytial virus KW - Infections KW - invasive fungal infections KW - Varicella-Zoster-Virus KW - Hepatitis B virus KW - Herpes simplex virus KW - Human immunodefiency virus KW - Low-dose acyclovir KW - Viral KW - Fungal KW - Bacteria Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-187587 VL - 95 IS - 9 ER - TY - JOUR A1 - Mousset, Sabine A1 - Buchheidt, Dieter A1 - Heinz, Werner A1 - Ruhnke, Markus A1 - Cornely, Oliver A. A1 - Egerer, Gerlinde A1 - Krüger, William A1 - Link, Hartmut A1 - Neumann, Silke A1 - Ostermann, Helmut A1 - Panse, Jens A1 - Penack, Olaf A1 - Rieger, Christina A1 - Schmidt-Hieber, Martin A1 - Silling, Gerda A1 - Südhoff, Thomas A1 - Ullmann, Andrew J. A1 - Wolf, Hans-Heinrich A1 - Maschmeyer, Georg A1 - Böhme, Angelika T1 - Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) JF - Annals of Hematology N2 - Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive Candida infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection. KW - cancer KW - invasive fungal infections KW - antifungals KW - mycoses KW - hematologic malignancies KW - aspergillosis KW - antifungal agents KW - invasive candidiasis Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121340 VL - 96 ER - TY - THES A1 - Heinz, Werner J. T1 - Identifikation und Charakterisierung von PHR3, einem zu der PHR/GAS-Familie homologen Gen bei Candida albicans T1 - Identification and characterization of PHR3, a gene homologous to the PHR/GAS familiy of candida albicans N2 - Es konnte mit PHR3 bei Candida albicans ein drittes GAS-homologes Gen nachgewiesen werden. Dieses weist überzeugende Übereinstimmungen der Nuklein- und Aminosäurensequenz und mit der fehlenden GPI-Verankerungsstelle und der pH-konstitutiven Expression auch interessante Unterschiede zu den bisher bekannten Genen der PHR-Familie auf. Eine funktionelle Homologie zu den weiteren PHR-Genen bei Candida albicans konnte nicht belegt werden. Es sind bisher in verschiedenen Spezies mehrere homologe Gene dieser Familie nachgewiesen worden. So sind auch bei Candida albicans weitere möglich und die endgültige Zahl der PHR-Gene wird erst nach Abschluß des Candida albicans-Genomprojektes bestimmt werden können. Der Zweck mehrerer homologer Gene ist insbesondere für die bei unterschiedlichen pH-Werten vorliegenden Proteine Phr1p und Phr2p noch nicht bekannt. Eine mögliche Erklärung ist, dass ihre Translation auf unterschiedliche Weise die Expression anderer Gene oder die Prozessierung und Funktion von Proteinen beeinflusst. Eine solche feine Regulation von Wachstums- und Virulenzfaktoren und somit eine Anpassung an Umweltbedingungen und Infektionswege ist für die Pathogenität von Candida albicans von Bedeutung. Die spezifischen Faktoren für die Induktion von PHR3 sind, sollte eine differenzierte Regulation vorliegen, dagegen ebenso wenig wie für GAS4, als nähestes verwandtes Gen, und für die weiteren GAS-Gene bekannt. Zum Nachweis einer solchen signalspezifischen Transkription sind Experimente mit anderen Versuchsanordnungen, mit welchen sich komplexere Milieus und Infektionswege untersuchen lassen, wie DNA-Chips oder induktionsabhängige Signalkassetten (Morschhäuser et al., 1999; Staib et al., 1999) hilfreich. Da eine fehlende C-terminale Region bei GAS1 zur Sekretion eines vergrößerten Proteins mit Hypermannosylierung der serinreichen Region führt (Popolo et Vai, 1998), erscheint auch eine extrazelluläre Funktion von Phr3p, welches dieses hydrophobe 3’ Ende nativ nicht besitzt, möglich. Dabei ist eine zu Phr1p und Phr2p ähnliche oder gleiche enzymatische Funktion, welche in Diskussion 112 unterschiedlichen Kompartimenten oder von unterschiedlicher Lokalisation aus den Aufbau der Zellwand beeinflusst, denkbar. KW - PHR3 KW - PHR/GAS KW - Candida albicans KW - PHR3 KW - PHR/GAS KW - candida albicans Y1 - 2001 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-1179719 ER - TY - JOUR A1 - Gründahl, Marie A1 - Wacker, Beate A1 - Einsele, Hermann A1 - Heinz, Werner J. T1 - Invasive fungal diseases in patients with new diagnosed acute lymphoblastic leukaemia JF - Mycoses N2 - Background Patients with acute leukaemia have a high incidence of fungal infections. This has primarily been shown in acute myeloid leukaemia and is different for acute lymphoblastic leukaemia. Until now no benefit of mould active prophylaxis has been demonstrated in the latter population. Methods In this retrospective single‐centre study, we analysed the incidence, clinical relevance, and outcome of invasive fungal diseases (IFD) as well as the impact of antifungal prophylaxis for the first 100 days following the primary diagnosis of acute lymphoblastic leukaemia. Results In 58 patients a high rate of proven, probable, and possible fungal infections could be demonstrated with a 3.4%, 8.6%, and 17.2% likelihood, respectively. The incidence might be even higher, as nearly 40% of all patients had no prolonged neutropenia for more than 10 days, excluding those from the European Organization of Research and Treatment of cancer and the Mycoses Study Group criteria for probable invasive fungal disease. The diagnosed fungal diseases had an impact on the duration of hospitalisation, which was 13 days longer for patients with proven/probable IFD compared to patients with no signs of fungal infection. Use of antifungal prophylaxis did not significantly affect the risk of fungal infection. Conclusion Patients with acute lymphoblastic leukaemia are at high risk of acquiring an invasive fungal disease. Appropriate criteria to define fungal infections, especially in this population, and strategies to reduce the risk of infection, including antifungal prophylaxis, need to be further evaluated. KW - acute lymphoblastic leukaemia KW - fungal infection KW - galactomannan KW - incidence KW - mortality Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-217844 VL - 63 IS - 10 SP - 1101 EP - 1106 ER - TY - JOUR A1 - Du, Baoguo A1 - Ma, Yuhua A1 - Yáñez‐Serrano, Ana Maria A1 - Arab, Leila A1 - Fasbender, Lukas A1 - Alfarraj, Saleh A1 - Albasher, Gadah A1 - Hedrich, Rainer A1 - White, Philip J. A1 - Werner, Christiane A1 - Rennenberg, Heinz T1 - Physiological responses of date palm (Phoenix dactylifera) seedlings to seawater and flooding JF - New Phytologist N2 - In their natural environment along coast lines, date palms are exposed to seawater inundation and, hence, combined stress by salinity and flooding. To elucidate the consequences of this combined stress on foliar gas exchange and metabolite abundances in leaves and roots, date palm seedlings were exposed to flooding with seawater and its major constituents under controlled conditions. Seawater flooding significantly reduced CO\(_{2}\) assimilation, transpiration and stomatal conductance, but did not affect isoprene emission. A similar effect was observed upon NaCl exposure. By contrast, flooding with distilled water or MgSO\(_{4}\) did not affect CO\(_{2}\)/H\(_{2}\)O gas exchange or stomatal conductance significantly, indicating that neither flooding itself, nor seawater sulfate, contributed greatly to stomatal closure. Seawater exposure increased Na and Cl contents in leaves and roots, but did not affect sulfate contents significantly. Metabolite analyses revealed reduced abundances of foliar compatible solutes, such as sugars and sugar alcohols, whereas nitrogen compounds accumulated in roots. Reduced transpiration upon seawater exposure may contribute to controlling the movement of toxic ions to leaves and, therefore, can be seen as a mechanism to cope with salinity. The present results indicate that date palm seedlings are tolerant towards seawater exposure to some extent, and highly tolerant to flooding. KW - compatible solutes and other metabolites KW - date palm KW - flooding KW - salinity KW - shoot–root interaction KW - stomatal conductance KW - sulfate Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228226 VL - 229 IS - 6 SP - 3318 EP - 3329 ER - TY - JOUR A1 - Spinner, Christoph D A1 - Wille, Florian A1 - Schwerdtfeger, Christiane A1 - Thies, Philipp A1 - Tanase, Ursula A1 - Von Figura, Guido A1 - Schmid, Roland M A1 - Heinz, Werner J A1 - Klinker, Hartwig Hf T1 - Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data JF - AIDS Research and Therapy N2 - Background: While HIV, AIDS and atypical Mycobacterium infections are closely linked, the use of Integrase-Inhibitor based cART, notably raltegravir-based regimens is more widespread. RAL should be double-dosed to 800 mg semi-daily in situation of rifampicin co-medication, because RAL is more rapidly metabolized due to rifampicin-induced Uridine-5'-diphosph-gluronosyl-transferase (UGT1A1). Recently, it was speculated that chewed RAL might lead to increased absorption, which might compensate the inductive effect of rifampicin-rapid metabolized RAL, as part of cost-saving effects in countries with high-tuberculosis prevalence and less economic power. Methods: We report measurement of raltegravir pharmacokinetics in a 34-year AIDS-patient suffering from disseminated Mycobacterium avium infection with necessity of parenteral rifampicin treatment. RAL levels were measured with HPLC (internal standard: carbamazepine, LLQ 11 ng/ml, validation with Valistat 2.0 program (Arvecon, Germany)). For statistical analysis, a two-sided Wilcoxon signed rank test for paired samples was used. Results: High intra-personal variability in raltegravir serum levels was seen. Comparable C\(_{max}\) concentrations were found for 800 mg chewed and swallowed RAL, as well as for 400 mg chewed and swallowed RAL. While C\(_{max}\) seems to be more dependent from overall RAL dosing than from swallowed or chewed tablets, increased AUC(12) is clearly linked to higher RAL dosages per administration. Anyway, chewed raltegravir showed a rapid decrease in serum levels. Conclusions: We found no evidence that chewed 400 mg semi-daily raltegravir in rifampicin co-medication leads to optimized pharmacokinetics. There is need for more data from randomized trials for further recommendations. KW - pharmacology KW - drug KW - HIV KW - chewed KW - Mycobacterium avium KW - raltegravir KW - pharmacokinetic Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144058 VL - 12 IS - 1 ER -